启迪药业集团股份公司（以下简称"公司"）于近日收到独立董事黄正 明先生递交的辞职报告。具体情况如下： 黄正明先生因工作原因决定辞去公司独立董事、战略委员会委员、提名 委员会委员、薪酬与考核委员会委员。截至本公告日，黄正明先生未持有公 司股份，不存在应履行而未履行的承诺事项。 黄正明先生的辞职将导致公司独立董事人数不足《公司章程》规定的董 事会人数的三分之一。根据相关法律法规，黄正明先生的辞职报告将在公司 股东大会选举产生新任独立董事后生效。在此期间，他将继续履行独立董事 及相关委员会职责。公司将尽快完成独立董事的补选工作。 黄正明先生在担任公司独立董事期间，恪尽职守、勤勉尽责，为公司 规范运作、科学决策发挥了积极作用。公司对黄正明先生在任职期间为公 司发展所做出的贡献表示衷心感谢。 特此公告。 证券代码：000590 证券简称：启迪药业 公告编号：2025-046 启迪药业集团股份公司 关于公司独立董事辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025年9月25日 启迪药业集团股份公司 董事会 ...

Core Viewpoint - The company has undergone a change in control, with new leadership appointments and committee restructuring following the acquisition of shares by Hunan Sailoxian Management Consulting Partnership [19][20][21]. Group 1: Board Resolutions - The company held its seventh meeting of the tenth board on September 23, 2025, where key resolutions were passed [13][21]. - Jiang Xin was elected as the chairman of the tenth board of directors [13][21]. - Jiang Xin and Zhou Yanqi were appointed as members of the board's strategic committee, with Jiang Xin serving as the chairman of this committee [3][4]. - Ni Xiaoqiao was appointed as a member of the board's audit committee [5][6]. - Jiang Xin was appointed as the company's president, and Qiao Xuefeng was appointed as the vice president [7][9]. Group 2: Change of Control - On July 15, 2025, Hunan Sailoxian successfully auctioned 58,606,962 shares from the original controlling shareholder, accounting for 24.47% of the company's total share capital [20]. - The transfer of ownership was completed on August 11, 2025, following the judicial auction [20]. - The change in control was finalized on September 22, 2025, with the election of Jiang Xin and Zhou Yanqi as non-independent directors [21].

Group 1 - The core announcement is the appointment of Mr. Jiang Xin as the President and Mr. Qiao Xuefeng as the Vice President of Qidi Pharmaceutical [1]

Core Viewpoint - The management and shareholder changes at Qidi Pharmaceutical are closely linked to the recent shift in control, marking a significant transition in the company's governance and strategic direction [2][4]. Group 1: Management Changes - Qidi Pharmaceutical's President Feng Xue and Vice President Cai Jun have resigned, with no future roles in the company [1]. - The company's chairman, Jiao Qisen, will remain in other internal positions despite stepping down as chairman [1]. - New board members from Hunan Sailoxian, the new controlling shareholder, have been appointed, indicating a shift in management focus [1]. Group 2: Shareholder Changes - Hunan Sailoxian acquired a 24.47% stake in Qidi Pharmaceutical for approximately 1 billion yuan, marking a significant change in ownership [4][5]. - Prior to this change, Qidi Pharmaceutical was primarily controlled by Qidi Technology Service Co., which held 24.47% of the shares [3][5]. - The acquisition price of 17.18 yuan per share was notably higher than the market price at the time of the transaction [5]. Group 3: Company History and Evolution - Qidi Pharmaceutical has undergone multiple name changes and ownership transitions since its inception as Hengyang Traditional Chinese Medicine Industry Co. in 1996 [2][3]. - The company has changed its name several times, reflecting its evolving business strategy and ownership structure [2][3]. Group 4: Financial Performance - Qidi Pharmaceutical's revenue and net profit have shown fluctuations, with recent figures indicating a decline in profitability [6][8]. - The company reported revenues of 3.01 billion yuan in 2021, with a net profit of 354.4 million yuan, but faced losses in subsequent years [8].

Core Viewpoint - Qidi Pharmaceutical (000590.SZ) has undergone a change in control, with Hunan Sailoxian becoming the controlling shareholder and Jiang Xin as the actual controller [1] Group 1: Corporate Governance Changes - The company held its first extraordinary general meeting on September 22, 2025, where it approved the proposal to supplement the 10th Board of Directors with Jiang Xin and Zhou Yanqi as non-independent directors [1] - On September 23, 2025, the company convened the 7th meeting of the 10th Board of Directors, electing Jiang Xin as the chairman and CEO, and made adjustments to various senior management personnel [1] Group 2: Shareholder and Control Structure - As of the announcement date, the change of control has been completed, with Hunan Sailoxian now as the controlling shareholder [1] - Hunan Sailoxian is committed to maintaining the stable development of the listed company's business and will comply with relevant laws and regulations regarding information disclosure obligations [1]

Group 1 - The company announced the election of Mr. Jiang Xin as the chairman of the tenth board of directors, effective from the date of board approval until the end of the term of the tenth board [1] - Mr. Jiang Xin has also been appointed as the president of the company, while Mr. Qiao Xuefeng has been appointed as the vice president, with their terms aligned with the board's tenure [1] - The chairman serves as the legal representative of the company according to the company's articles of association and relevant regulations [1]

证券代码：000590 证券简称：启迪药业 公告编号：2025-044 启迪药业集团股份公司 关于选举董事长及聘任总裁、副总裁的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 启迪药业集团股份公司（以下简称"公司"）于2025年9月23日召开第 十次董事会第七次会议，审议通过了《关于选举公司第十届董事会董事长 的议案》《关于聘任公司高级管理人员的议案》现将具体情况公告如下： 一、选举第十届董事会董事长 经董事会审议，选举江琎先生担任公司第十届董事会董事长，任期自董 事会审议通过之日起至第十届董事会任期届满之日止。 根据《公司章程》等相关规定，董事长为公司法定代表人。公司将根据 有关规定办理工商变更登记等后续事项。 二、聘任公司总裁、副总裁 经董事会审议，聘任江琎先生担任公司总裁、乔雪峰先生担任公司副总 裁。上述人员任期自董事会审议通过之日起至第十届董事会任期届满之日止。 江琎先生、乔雪峰先生简历详见附件。 特此公告。 启迪药业集团股份公司 董事会 2025年9月24日 附件 江琎先生简历 江琎先生，1984年12月出生，中国国籍，无其他国家或者地区的国籍 ...

证券代码：000590 证券简称：启迪药业 公告编号：2025-043 委员名单：江琎、倪小桥、周延奇、黄正明、黄文表 启迪药业集团股份公司 第十届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 启迪药业集团股份公司（以下简称"公司"）第十届董事会第七次会议通知于 2025 年 9 月 12 日通过电子邮件的方式发出。会议于 2025 年 9 月 23 日以现场与 通讯相结合方式召开。会议由副董事长倪小桥先生主持，会议应出席董事 7 人， 实际出席董事 7 人，其中以通讯方式表决 2 人，无委托出席情况。公司监事、高 级管理人员列席了会议，会议的召开、表决程序符合《公司法》及《公司章程》 的规定。会议经过充分讨论与审议形成如下决议： 一、通过《关于选举公司第十届董事会董事长的议案》； 选举江琎先生为公司第十届董事会董事长。 表决结果：7 票赞成，0 票反对，0 票弃权。 二、通过《关于补选公司董事会战略委员会委员的议案》； 公司董事会提名补选江琎先生、周延奇先生为董事会战略委员会委员，其中 江琎先生为主任委员。 补选后的委员组成为： ...

（记者 曾健辉） 每经AI快讯，启迪药业9月23日晚间发布公告称，公司于2025年9月22日召开2025年第一次临时股东大 会，审议通过了《关于补选公司第十届董事会董事的议案》，经股东湖南赛乐仙提名，补选江琎先生、 周延奇先生为非独立董事；2025年9月23日，公司召开第十届董事会第七次会议，选举江琎先生为公司 董事长兼总裁，补选董事会下设各委员会的相应委员并调整了部分高级管理人员。基于公司股权结构、 湖南赛乐仙持股比例及公司董事会等治理架构调整情况，公司控股股东变更为湖南赛乐仙，实际控制人 为江琎。 每经头条（nbdtoutiao）——报价太低遭严防，投标企业还得"解释清楚"，一场国家组织的大型采购， 为何引发全行业关注 ...

Core Points - The company announced the election of Mr. Jiang Xin as the chairman of the board and the appointment of Mr. Jiang Xin as the president and Mr. Qiao Xuefeng as the vice president [1] - Mr. Jiang Xin does not directly hold shares in the company but holds shares indirectly through the controlling shareholder Hunan Sailoxian [1] - Mr. Qiao Xuefeng holds 7,200 shares in the company [1]